Clinical Trial Update: Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety? [Phase 3]

View source ↗

Summary

Phase 3 trial investigating whether initial response to low-dose risperidone predicts outcomes in anxiety; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorder
• Anxiety State

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Marion Trousselard | Conditions: Anxiety State | Phase 3 | Status: TERMINATED